Abstract
Anti-interleukin 17A agent, secukinumab is remarkably effective for treating patients with ankylosing spondylitis. However, the main safety concern of secukinumab is an increased risk of infection. Generally, neurosyphilis occurs a few years after the primary syphilitic infection. Rare cases of progressing to neurosyphilis with a much lower latency were reported. We report a case of rapid progressive neurosyphilis involving hearing loss in both ears in a patient with ankylosing spondylitis who was treated with secukinumab.
| Original language | English |
|---|---|
| Pages (from-to) | 278-281 |
| Number of pages | 4 |
| Journal | Journal of Rheumatic Diseases |
| Volume | 26 |
| Issue number | 4 |
| DOIs | |
| State | Published - Oct 2019 |
Keywords
- Ankylosing spondylitis
- Interleukin 17A
- Neurosyphilis
Fingerprint
Dive into the research topics of 'A Case of Rapid Progressive Neurosyphilis in Patient with Ankylosing Spondylitis Who Is Treating Anti-interleukin 17A Monoclonal Antibody, Secukinumab'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver